II. AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all previous listings.

1. (original) A compound of formula I



I

wherein R is (C_{1-40})alkyl or (C_{1-40})alkenyl, in free base or acid addition salt form.

2. (cancelled)

3. (currently amended) The compound of claim 1, wherein the compound is useful ~~suitable for use~~ as a pharmaceutical.

4. (currently amended) The compound of claim 1, wherein the compound is useful ~~suitable for use~~ in the treatment of a psychotic disorder.

5. (original) The compound of claim 4, wherein the psychotic disorder is selected from a group consisting of: schizophrenia and a bipolar disorder.

6. (cancelled)

7. (original) A method for the production of the compounds of formula I



I

wherein R is (C_{1-40})alkyl or (C_{1-40}) alkenyl, and their salts, the method comprising:

reacting a compound of formula II



II

with a compound of formula III



III

wherein R is (C_{1-40})alkyl or (C_{1-40})alkenyl and X is halogen; and

recovering the resulting compound in free base or acid addition salt form.

8. (original) The method of claim 7, wherein the acid addition salt form includes a pharmaceutically acceptable acid addition salt form.

9. (currently amended) The method of claim 7, wherein the compound is useful ~~suitable for use~~ as a pharmaceutical.

10. (currently amended) The method ~~compound~~ of claim 7, wherein the compound is useful ~~suitable for use~~ in the treatment of a psychotic disorder.

11. (currently amended) The method ~~compound~~ of claim 10, wherein the psychotic disorder is selected from a group consisting of: schizophrenia and a bipolar disorder.

12. (currently amended) The method ~~compound~~ of claim 7, further comprising a pharmaceutical carrier or diluent.

13. (withdrawn) A method for the treatment of a psychotic disorder in a subject in need of such treatment, the method comprising:

administering to the subject a therapeutically effective amount of a compound of formula I



I

wherein R is (C_{1-40})alkyl or (C_{1-40})alkenyl, in free base or pharmaceutically acceptable acid addition salt form.

14. (withdrawn) The method of claim 13, wherein administering includes at least one of the following: parenteral administration and transdermal administration.

15. (withdrawn) The method of claim 13, wherein an effective amount includes an amount between about 0.1 mg/kg and about 500 mg/kg of body weight of the subject.

16. (withdrawn) The method of claim 15, wherein an effective amount includes an amount between about 0.5 mg/kg and about 100 mg/kg of body weight of the subject.

17. (withdrawn) The method of claim 13, wherein the subject is a human.

18. (original) The method of claim 17, wherein an effective amount includes a daily dosage between about 10 mg and about 2000 mg.

19. (cancelled)

20. (withdrawn) The method of claim 13, wherein the compound of formula I is administered in a sustained release form.

21. (new) The compound of claim 1 in free base form.

22. (new) The compound of claim 1 in acid addition salt form, wherein the acid is a pharmaceutically acceptable acid.

23. (new) A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutical carrier or diluent.